Home » FDA Draft Guidance Recommends PK Studies for Some Patients
FDA Draft Guidance Recommends PK Studies for Some Patients
April 15, 2010
Sponsors should conduct pharmacokinetic (PK) studies in patients with kidney damage as part of clinical development for most investigational drugs intended
for chronic use, a U.S. Food and Drug Administration (FDA) draft guidance says.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor